IEHP UM Subcommittee Approved Authorization Guideline

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Bronchial Thermoplasty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline #</td>
<td>UM_SUR 10</td>
</tr>
<tr>
<td>Original Effective Date</td>
<td>May 9, 2018</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Surgical Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision Date</td>
<td></td>
</tr>
</tbody>
</table>

**COVERAGE POLICY**

Bronchial Thermoplasty (BT) may be considered medically necessary when ALL the following criteria are met:

A. The patient has been managed by an asthma specialist (pulmonologist, allergist, immunologist) for at least six months prior to consideration of BT

B. The patient is 18 years of age or older

C. The patient is a current non-smoker

D. There is documentation that the patient is compliant with preferred asthma medications, and has received training in asthma self-management (e.g., self-monitoring of symptoms and/or Peak Expiratory Flow (PEF), written asthma action plan, and regular medical review).

E. The patient has been diagnosed with chronic, severe persistent asthma that has failed or not tolerated maximum therapy (defined below);

1. Severe persistent asthma is defined as:
   a. Documented current use of an inhaled corticosteroid for at least six consecutive months; AND
   b. Documented current use of an additional controller medication including long-acting beta agonist, long-acting muscarinic antagonist or leukotriene inhibitor for at least six consecutive months; AND
   c. Documentation that patient’s co-morbidities have been reviewed, addressed and are being treated appropriately; AND
   d. The patient is taking, or is being considered for, chronic oral corticosteroids to maintain asthma control; AND
   e. The patient is not a candidate for, or has failed a three month trial of biologic therapy (such as anti-IgE, anti-IL5) with no change in symptom severity

2. Severe persistent asthma therapy that has not been effective or is not well tolerated is defined by at least one of the following:
   a. Poor symptom control as evidenced by the presence of greater than or equal to three of the following:
      i. Daytime asthma symptom more than twice per week
      ii. Any night waking due to asthma
      iii. Need for symptom relief more than twice per week
      iv. Any activity limitation due to asthma
   b. Asthma Control Test (ACT) less than 20 (Appendix A)
   c. Two or more serious attacks, hospitalizations, ED visits, or exacerbations requiring systemic corticosteroids within the past 12 months
COVERAGE LIMITATIONS AND EXCLUSIONS

A. One complete thermoplasty procedure must be performed in three treatment sessions with a recovery period of 2 weeks or longer between sessions.
B. Repeat procedures of bronchial thermoplasty, beyond the initial three treatments are not covered because it has not been shown to improve long-term health outcomes.
C. Bronchial thermoplasty is not covered for any other indications than outlined in criteria.
D. Bronchial thermoplasty must be performed by clinicians experienced in bronchoscopy and who have completed bronchial thermoplasty training and are certified to perform BT by Boston Scientific.
E. Contraindications
   1. Patients are unable to undergo bronchoscopy safely
   2. Presence of a pacemaker, internal defibrillator, or other implantable electronic devices
   3. Known hypersensitivity to drugs used during bronchoscopy such as lidocaine, midazolam, fentanyl
   4. Severe comorbid conditions that would increase the risk of adverse events during the procedure based on an assessment by the proceduralist.

ADDITIONAL INFORMATION

None

CLINICAL/REGULATORY RESOURCE

None

DEFINITION OF TERMS

None

REFERENCES


DISCLAIMER
IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.